Key Takeaways & Executive Findings
- •• Combination of carvedilol and sorafenib synergistically inhibits HCC cell proliferation and induces apoptosis. • In vivo, the combination significantly reduces tumor growth compared to either drug alone. • The synergistic effect is mediated via suppression of the PI3K/Akt/mTOR signaling pathway. • This combination therapy may offer a new treatment option for advanced HCC patients.
Abstract
Background: Carvedilol, a non-selective beta-blocker, has shown potential anti-tumor effects in hepatocellular carcinoma (HCC). However, its efficacy as a monotherapy is limited. This study investigates the synergistic effects of carvedilol combined with sorafenib, a multi-kinase inhibitor, in HCC treatment. Methods: In vitro assays were performed using HCC cell lines (HepG2 and Huh7) to assess cell viability, apoptosis, and migration. In vivo, a xenograft mouse model was used to evaluate tumor growth inhibition. Molecular mechanisms were explored via Western blotting and qRT-PCR. Results: Combination therapy significantly reduced cell viability and induced apoptosis compared to monotherapies. Tumor growth in vivo was markedly suppressed in the combination group. Mechanistically, the combination downregulated the PI3K/Akt/mTOR pathway and upregulated pro-apoptotic proteins. Conclusion: Carvedilol enhances the anti-tumor efficacy of sorafenib in HCC, suggesting a promising therapeutic strategy.
1. Introduction
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer-related mortality worldwide. Despite advances in surgical resection, liver transplantation, and locoregional therapies, the prognosis for advanced HCC remains poor. Systemic therapies, including tyrosine kinase inhibitors like sorafenib, have been the standard of care, but their efficacy is limited by drug resistance and adverse effects.
Carvedilol, a third-generation beta-blocker, has been shown to possess anti-proliferative and pro-apoptotic properties in various cancer types. Its potential in HCC has been suggested by retrospective studies, but the underlying mechanisms are not fully understood. This study aims to investigate whether carvedilol can enhance the anti-tumor effects of sorafenib in HCC, both in vitro and in vivo, and to elucidate the molecular pathways involved.
Loading authentic research manuscript (Pages 1–5)...
Y. Zhang, L. Wang, H. Li, J. Chen, X. Liu (2026). Enhancing the Efficacy of Carvedilol in Hepatocellular Carcinoma: A Comprehensive Analysis of Combination Therapy with Sorafenib. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main finding of this study?
The study demonstrates that carvedilol combined with sorafenib synergistically inhibits HCC cell growth and induces apoptosis, with significant tumor suppression in a mouse model.
How does carvedilol enhance the efficacy of sorafenib?
The combination downregulates the PI3K/Akt/mTOR signaling pathway and upregulates pro-apoptotic proteins, leading to enhanced anti-tumor effects.
What are the implications for HCC treatment?
This combination therapy could provide a new treatment strategy for advanced HCC, potentially improving outcomes and overcoming resistance to sorafenib.
Were there any adverse effects observed?
The study primarily focused on efficacy; however, the combination was well-tolerated in the animal model, with no significant additional toxicity compared to sorafenib alone.
What are the next steps for this research?
Further clinical trials are needed to validate the safety and efficacy of this combination in HCC patients, and to explore biomarkers for patient selection.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.